ArticleClinics (Sao Paulo, Brazil)2026
A serum Golgi Protein 73 (GP73)-based model for evaluating inflammation associated with drug-induced liver injury.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic utility of serum Golgi Protein-73 (GP73) in staging hepatic inflammatory activity and evaluating fibrosis in patients with Drug-Induced Liver Injury (DILI).
methodsA retrospective analysis was conducted on 130 patients with DILI who underwent liver biopsy. Patients were categorized according to inflammation grade (G0∼G1: n = 49, G2∼G3: n = 62, G4: n = 19) and fibrosis stages (S0∼S1: n = 24, S2∼S3: n = 45, S4: n = 14). Correlations between GP73 levels and markers of liver inflammation, fibrosis, and biochemical indicators were examined. Logistic regression and ROC curves evaluated diagnostic precision.
resultsSerum GP73 levels exhibited a positive correlation with liver injury markers such as ALT, AST, TBIL, ALP, HA, PC-III, and APRI (p < 0.05), while demonstrating a negative correlation with ALB, CHE, PA, and FIB (p < 0.05). GP73 and ALB were recognized as independent risk factors for hepatic inflammation (p < 0.05). The integrated diagnostic efficacy of GP73 and ALB for moderate (G ≥ 2) and severe inflammation (G ≥ 3) produced AUCs of 0.860 and 0.945, respectively, surpassing those of ALT and AST (AUCs: 0.679, 0.716 and 0.762, 0.805, respectively). When ALT levels were normal, the combined AUCs of GP73 and ALB for diagnosing moderate (G ≥ 2) and severe inflammation (G ≥ 3) were 0.853 and 0.987, respectively. Furthermore, GP73 was identified as an independent predictor of fibrosis (p < 0.05), exhibiting AUCs of 0.707 and 0.856 for moderate and severe fibrosis, respectively, indicating enhanced diagnostic efficacy relative to FIB-4 and APRI.
conclusionGP73 is significantly increased in the serum of patients experiencing drug-induced liver injury. GP73, whether utilized independently or alongside other diagnostic methods, exhibits significant potential for evaluating liver inflammation and fibrosis. Its efficacy in diagnosing liver inflammation exceeds its utility for fibrosis, potentially reducing the necessity for liver biopsy procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.